Targeted Drug BRAF Inhibitors for NSCLC Market Report

China Targeted Drug BRAF Inhibitors for NSCLC Market Professional Research Report 2022-2027, Segmented by Players, Types, End-Users in Major Regions

  • POSTDATE：Aug 21, 2022
  • PAGES：160
  • REPORT CODE：GMM1054555
  • REPORT SUMMARY
  • TABLE OF CONTENTS

  • This report offers an overview of the market trends, drivers, and barriers with respect to the China Targeted Drug BRAF Inhibitors for NSCLC market. It also provides a detailed overview of the market of different regions across North China, Central China, South China, East China, Northeast China, Southwest China, Northwest China. The report deep analyzes type and application in China Targeted Drug BRAF Inhibitors for NSCLC market. Detailed analysis of key players, along with key growth strategies adopted by Targeted Drug BRAF Inhibitors for NSCLC industry, the PEST and SWOT analysis are also included. In short, the report will provide a comprehensive view of the industry's development and features.

    By Player:

    • BeiGene

    • Novartis

    By Type:

    • Dabrafenib

    • Trametinib

    • Lifirafenib

    • Other

    By End-User:

    • Squamous Cell Carcinoma of NSCLC

    • Adenocarcinoma of NSCLC

    • Large Cell Carcinoma of NSCLC

    By Region:

    • North China

    • Central China

    • South China

    • East China

    • Northeast China

    • Southwest China

    • Northwest China

  • TABLE OF CONTENT

    1 Report Overview

    • 1.1 Product Definition and Scope

    • 1.2 PEST (Political, Economic, Social and Technological) Analysis of Targeted Drug BRAF Inhibitors for NSCLC Market

    • 1.3 Market Segment by Type

    • 1.3.1 China Targeted Drug BRAF Inhibitors for NSCLC Market Size and Growth Rate of Dabrafenib from 2016 to 2027

    • 1.3.2 China Targeted Drug BRAF Inhibitors for NSCLC Market Size and Growth Rate of Trametinib from 2016 to 2027

    • 1.3.3 China Targeted Drug BRAF Inhibitors for NSCLC Market Size and Growth Rate of Lifirafenib from 2016 to 2027

    • 1.3.4 China Targeted Drug BRAF Inhibitors for NSCLC Market Size and Growth Rate of Other from 2016 to 2027

    • 1.4 Market Segment by Application

    • 1.4.1 China Targeted Drug BRAF Inhibitors for NSCLC Market Size and Growth Rate of Squamous Cell Carcinoma of NSCLC from 2016 to 2027

    • 1.4.2 China Targeted Drug BRAF Inhibitors for NSCLC Market Size and Growth Rate of Adenocarcinoma of NSCLC from 2016 to 2027

    • 1.4.3 China Targeted Drug BRAF Inhibitors for NSCLC Market Size and Growth Rate of Large Cell Carcinoma of NSCLC from 2016 to 2027

    • 1.5 Market Segment by Regions

      • 1.5.1 North China Targeted Drug BRAF Inhibitors for NSCLC Consumption Market Size and Growth Rate from 2016 to 2027

      • 1.5.2 Central China Targeted Drug BRAF Inhibitors for NSCLC Consumption Market Size and Growth Rate from 2016 to 2027

      • 1.5.3 South China Targeted Drug BRAF Inhibitors for NSCLC Consumption Market Size and Growth Rate from 2016 to 2027

      • 1.5.4 East China Targeted Drug BRAF Inhibitors for NSCLC Consumption Market Size and Growth Rate from 2016 to 2027

      • 1.5.5 Northeast China Targeted Drug BRAF Inhibitors for NSCLC Consumption Market Size and Growth Rate from 2016 to 2027

      • 1.5.6 Southwest China Targeted Drug BRAF Inhibitors for NSCLC Consumption Market Size and Growth Rate from 2016 to 2027

      • 1.5.7 Northwest China Targeted Drug BRAF Inhibitors for NSCLC Consumption Market Size and Growth Rate from 2016 to 2027

    2 Market Trends and Competitive Landscape

    • 2.1 Market Trends and Dynamics

      • 2.1.1 Market Challenges and Restraints

      • 2.1.2 Market Opportunities and Potentials

      • 2.1.3 Mergers and Acquisitions

    • 2.2 Competitive Landscape Analysis

      • 2.2.1 Industrial Concentration Analysis

      • 2.2.2 Porter's Five Forces Analysis of the Industry

      • 2.2.3 SWOT Analysis for New Entrants

    • 2.3 Coronavirus (COVID-19) Distribution and its Impact on the Industry

    3 Segmentation of Targeted Drug BRAF Inhibitors for NSCLC Market by Types

    • 3.1 Products Development Trends of Different Types

    • 3.2 Commercial Products Types of Major Vendors

    • 3.3 Competitive Landscape Analysis of Different Types

    • 3.4 Market Size of Targeted Drug BRAF Inhibitors for NSCLC by Major Types

    • 3.4.1 Market Size and Growth Rate of Dabrafenib

    • 3.4.2 Market Size and Growth Rate of Trametinib

    • 3.4.3 Market Size and Growth Rate of Lifirafenib

    • 3.4.4 Market Size and Growth Rate of Other

    4 Segmentation of Targeted Drug BRAF Inhibitors for NSCLC Market by End-Users

    • 4.1 Downstream Client Analysis by End-Users

    • 4.2 Competitive Landscape Analysis of Different End-Users

    • 4.3 Market Potential Analysis of Different End-Users

    • 4.4 Market Size of Targeted Drug BRAF Inhibitors for NSCLC by Major End-Users

    • 4.4.1 Market Size and Growth Rate of Targeted Drug BRAF Inhibitors for NSCLC in Squamous Cell Carcinoma of NSCLC

    • 4.4.2 Market Size and Growth Rate of Targeted Drug BRAF Inhibitors for NSCLC in Adenocarcinoma of NSCLC

    • 4.4.3 Market Size and Growth Rate of Targeted Drug BRAF Inhibitors for NSCLC in Large Cell Carcinoma of NSCLC

    5 Market Analysis by Regions

    • 5.1 China Targeted Drug BRAF Inhibitors for NSCLC Production Analysis by Regions

    • 5.2 China Targeted Drug BRAF Inhibitors for NSCLC Consumption Analysis by Regions

    • 5.3 Coronavirus (COVID-19) Impact on China Economy

    6 North China Targeted Drug BRAF Inhibitors for NSCLC Landscape Analysis

    • 6.1 North China Targeted Drug BRAF Inhibitors for NSCLC Landscape Analysis by Major Types

    • 6.2 North China Targeted Drug BRAF Inhibitors for NSCLC Landscape Analysis by Major End-Users

    7 Central China Targeted Drug BRAF Inhibitors for NSCLC Landscape Analysis

    • 7.1 Central China Targeted Drug BRAF Inhibitors for NSCLC Landscape Analysis by Major Types

    • 7.2 Central China Targeted Drug BRAF Inhibitors for NSCLC Landscape Analysis by Major End-Users

    8 South China Targeted Drug BRAF Inhibitors for NSCLC Landscape Analysis

    • 8.1 South China Targeted Drug BRAF Inhibitors for NSCLC Landscape Analysis by Major Types

    • 8.2 South China Targeted Drug BRAF Inhibitors for NSCLC Landscape Analysis by Major End-Users

    9 East China Targeted Drug BRAF Inhibitors for NSCLC Landscape Analysis

    • 9.1 East China Targeted Drug BRAF Inhibitors for NSCLC Landscape Analysis by Major Types

    • 9.2 East China Targeted Drug BRAF Inhibitors for NSCLC Landscape Analysis by Major End-Users

    10 Northeast China Targeted Drug BRAF Inhibitors for NSCLC Landscape Analysis

    • 10.1 Northeast China Targeted Drug BRAF Inhibitors for NSCLC Landscape Analysis by Major Types

    • 10.2 Northeast China Targeted Drug BRAF Inhibitors for NSCLC Landscape Analysis by Major End-Users

    11 Southwest China Targeted Drug BRAF Inhibitors for NSCLC Landscape Analysis

    • 11.1 Southwest China Targeted Drug BRAF Inhibitors for NSCLC Landscape Analysis by Major Types

    • 11.2 Southwest China Targeted Drug BRAF Inhibitors for NSCLC Landscape Analysis by Major End-Users

    12 Northwest China Targeted Drug BRAF Inhibitors for NSCLC Landscape Analysis

    • 12.1 Northwest China Targeted Drug BRAF Inhibitors for NSCLC Landscape Analysis by Major Types

    • 12.2 Northwest China Targeted Drug BRAF Inhibitors for NSCLC Landscape Analysis by Major End-Users

    13 Major Players Profiles

    • 13.1 BeiGene

      • 13.1.1 BeiGene Company Profile and Recent Development

      • 13.1.2 Market Performance

      • 13.1.3 Product and Service Introduction

    • 13.2 Novartis

      • 13.2.1 Novartis Company Profile and Recent Development

      • 13.2.2 Market Performance

      • 13.2.3 Product and Service Introduction

    The List of Tables and Figures

    • Figure Product Picture

    • Figure China Targeted Drug BRAF Inhibitors for NSCLC Market Size and Growth Rate of Dabrafenib from 2016 to 2027

    • Figure China Targeted Drug BRAF Inhibitors for NSCLC Market Size and Growth Rate of Trametinib from 2016 to 2027

    • Figure China Targeted Drug BRAF Inhibitors for NSCLC Market Size and Growth Rate of Lifirafenib from 2016 to 2027

    • Figure China Targeted Drug BRAF Inhibitors for NSCLC Market Size and Growth Rate of Other from 2016 to 2027

    • Figure Market Share by Type in 2016

    • Figure Market Share by Type in 2021

    • Figure Market Share by Type in 2027

    • Figure China Targeted Drug BRAF Inhibitors for NSCLC Market Size and Growth Rate of Squamous Cell Carcinoma of NSCLC from 2016 to 2027

    • Figure China Targeted Drug BRAF Inhibitors for NSCLC Market Size and Growth Rate of Adenocarcinoma of NSCLC from 2016 to 2027

    • Figure China Targeted Drug BRAF Inhibitors for NSCLC Market Size and Growth Rate of Large Cell Carcinoma of NSCLC from 2016 to 2027

    • Figure Market Share by End-User in 2016

    • Figure Market Share by End-User in 2021

    • Figure Market Share by End-User in 2027

    • Figure North China Targeted Drug BRAF Inhibitors for NSCLC Consumption Market Size and Growth Rate from 2016 to 2027

    • Figure Central China Targeted Drug BRAF Inhibitors for NSCLC Consumption Market Size and Growth Rate from 2016 to 2027

    • Figure South China Targeted Drug BRAF Inhibitors for NSCLC Consumption Market Size and Growth Rate from 2016 to 2027

    • Figure East China Targeted Drug BRAF Inhibitors for NSCLC Consumption Market Size and Growth Rate from 2016 to 2027

    • Figure Northeast China Targeted Drug BRAF Inhibitors for NSCLC Consumption Market Size and Growth Rate from 2016 to 2027

    • Figure Southwest China Targeted Drug BRAF Inhibitors for NSCLC Consumption Market Size and Growth Rate from 2016 to 2027

    • Figure Northwest China Targeted Drug BRAF Inhibitors for NSCLC Consumption Market Size and Growth Rate from 2016 to 2027

    • Figure Development Trends and Industry Dynamics of Targeted Drug BRAF Inhibitors for NSCLC Industry

    • Figure Market Challenges and Restraints

    • Figure Market Opportunities and Potentials

    • Table Mergers and Acquisition

    • Figure Market Share of TOP 3 Players in 2020

    • Figure Market Share of TOP 5 Players in 2021

    • Figure Market Share of TOP 6 Players from 2016 to 2021

    • Figure Porter's Five Forces Analysis

    • Figure New Entrant SWOT Analysis

    • Figure Coronavirus (COVID-19) Map of China

    • Table Coronavirus (COVID-19) Impact on the Industry

    • Figure Specifications of Different Types of Targeted Drug BRAF Inhibitors for NSCLC

    • Figure Development Trends of Different Types

    • Table Commercial Products Types of Major Vendors

    • Figure Competitive Landscape Analysis of Different Types

    • Table Consumption of Targeted Drug BRAF Inhibitors for NSCLC by Different Types from 2016 to 2027

    • Table Consumption Share of Targeted Drug BRAF Inhibitors for NSCLC by Different Types from 2016 to 2027

    • Figure Market Size and Growth Rate of Dabrafenib

    • Figure Market Size and Growth Rate of Trametinib

    • Figure Market Size and Growth Rate of Lifirafenib

    • Figure Market Size and Growth Rate of Other

    • Table Downstream Client Analysis by End-Users

    • Figure Competitive Landscape Analysis of Different End-Users

    • Table Market Potential Analysis of Different End-Users

    • Figure Consumption of Targeted Drug BRAF Inhibitors for NSCLC by Different End-Users from 2016 to 2027

    • Table Consumption Share of Targeted Drug BRAF Inhibitors for NSCLC by Different End-Users from 2016 to 2027

    • Figure Market Size and Growth Rate of Squamous Cell Carcinoma of NSCLC

    • Figure Market Size and Growth Rate of Adenocarcinoma of NSCLC

    • Figure Market Size and Growth Rate of Large Cell Carcinoma of NSCLC

    • Table China Targeted Drug BRAF Inhibitors for NSCLC Production by Regions

    • Table China Targeted Drug BRAF Inhibitors for NSCLC Production Share by Regions

    • Figure China Targeted Drug BRAF Inhibitors for NSCLC Production Share by Regions in 2016

    • Figure China Targeted Drug BRAF Inhibitors for NSCLC Production Share by Regions in 2021

    • Figure China Targeted Drug BRAF Inhibitors for NSCLC Production Share by Regions in 2027

    • Table China Targeted Drug BRAF Inhibitors for NSCLC Consumption by Regions

    • Table China Targeted Drug BRAF Inhibitors for NSCLC Consumption Share by Regions

    • Figure China Targeted Drug BRAF Inhibitors for NSCLC Consumption Share by Regions in 2016

    • Figure China Targeted Drug BRAF Inhibitors for NSCLC Consumption Share by Regions in 2021

    • Figure China Targeted Drug BRAF Inhibitors for NSCLC Consumption Share by Regions in 2027

    • Table North China Targeted Drug BRAF Inhibitors for NSCLC Consumption by Types from 2016 to 2027

    • Table North China Targeted Drug BRAF Inhibitors for NSCLC Consumption Share by Types from 2016 to 2027

    • Figure North China Targeted Drug BRAF Inhibitors for NSCLC Consumption Share by Types in 2016

    • Figure North China Targeted Drug BRAF Inhibitors for NSCLC Consumption Share by Types in 2021

    • Figure North China Targeted Drug BRAF Inhibitors for NSCLC Consumption Share by Types in 2027

    • Table North China Targeted Drug BRAF Inhibitors for NSCLC Consumption by End-Users from 2016 to 2027

    • Table North China Targeted Drug BRAF Inhibitors for NSCLC Consumption Share by End-Users from 2016 to 2027

    • Figure North China Targeted Drug BRAF Inhibitors for NSCLC Consumption Share by End-Users in 2016

    • Figure North China Targeted Drug BRAF Inhibitors for NSCLC Consumption Share by End-Users in 2021

    • Figure North China Targeted Drug BRAF Inhibitors for NSCLC Consumption Share by End-Users in 2027

    • Table Central China Targeted Drug BRAF Inhibitors for NSCLC Consumption by Types from 2016 to 2027

    • Table Central China Targeted Drug BRAF Inhibitors for NSCLC Consumption Share by Types from 2016 to 2027

    • Figure Central China Targeted Drug BRAF Inhibitors for NSCLC Consumption Share by Types in 2016

    • Figure Central China Targeted Drug BRAF Inhibitors for NSCLC Consumption Share by Types in 2021

    • Figure Central China Targeted Drug BRAF Inhibitors for NSCLC Consumption Share by Types in 2027

    • Table Central China Targeted Drug BRAF Inhibitors for NSCLC Consumption by End-Users from 2016 to 2027

    • Table Central China Targeted Drug BRAF Inhibitors for NSCLC Consumption Share by End-Users from 2016 to 2027

    • Figure Central China Targeted Drug BRAF Inhibitors for NSCLC Consumption Share by End-Users in 2016

    • Figure Central China Targeted Drug BRAF Inhibitors for NSCLC Consumption Share by End-Users in 2021

    • Figure Central China Targeted Drug BRAF Inhibitors for NSCLC Consumption Share by End-Users in 2027

    • Table South China Targeted Drug BRAF Inhibitors for NSCLC Consumption by Types from 2016 to 2027

    • Table South China Targeted Drug BRAF Inhibitors for NSCLC Consumption Share by Types from 2016 to 2027

    • Figure South China Targeted Drug BRAF Inhibitors for NSCLC Consumption Share by Types in 2016

    • Figure South China Targeted Drug BRAF Inhibitors for NSCLC Consumption Share by Types in 2021

    • Figure South China Targeted Drug BRAF Inhibitors for NSCLC Consumption Share by Types in 2027

    • Table South China Targeted Drug BRAF Inhibitors for NSCLC Consumption by End-Users from 2016 to 2027

    • Table South China Targeted Drug BRAF Inhibitors for NSCLC Consumption Share by End-Users from 2016 to 2027

    • Figure South China Targeted Drug BRAF Inhibitors for NSCLC Consumption Share by End-Users in 2016

    • Figure South China Targeted Drug BRAF Inhibitors for NSCLC Consumption Share by End-Users in 2021

    • Figure South China Targeted Drug BRAF Inhibitors for NSCLC Consumption Share by End-Users in 2027

    • Table East China Targeted Drug BRAF Inhibitors for NSCLC Consumption by Types from 2016 to 2027

    • Table East China Targeted Drug BRAF Inhibitors for NSCLC Consumption Share by Types from 2016 to 2027

    • Figure East China Targeted Drug BRAF Inhibitors for NSCLC Consumption Share by Types in 2016

    • Figure East China Targeted Drug BRAF Inhibitors for NSCLC Consumption Share by Types in 2021

    • Figure East China Targeted Drug BRAF Inhibitors for NSCLC Consumption Share by Types in 2027

    • Table East China Targeted Drug BRAF Inhibitors for NSCLC Consumption by End-Users from 2016 to 2027

    • Table East China Targeted Drug BRAF Inhibitors for NSCLC Consumption Share by End-Users from 2016 to 2027

    • Figure East China Targeted Drug BRAF Inhibitors for NSCLC Consumption Share by End-Users in 2016

    • Figure East China Targeted Drug BRAF Inhibitors for NSCLC Consumption Share by End-Users in 2021

    • Figure East China Targeted Drug BRAF Inhibitors for NSCLC Consumption Share by End-Users in 2027

    • Table Northeast China Targeted Drug BRAF Inhibitors for NSCLC Consumption by Types from 2016 to 2027

    • Table Northeast China Targeted Drug BRAF Inhibitors for NSCLC Consumption Share by Types from 2016 to 2027

    • Figure Northeast China Targeted Drug BRAF Inhibitors for NSCLC Consumption Share by Types in 2016

    • Figure Northeast China Targeted Drug BRAF Inhibitors for NSCLC Consumption Share by Types in 2021

    • Figure Northeast China Targeted Drug BRAF Inhibitors for NSCLC Consumption Share by Types in 2027

    • Table Northeast China Targeted Drug BRAF Inhibitors for NSCLC Consumption by End-Users from 2016 to 2027

    • Table Northeast China Targeted Drug BRAF Inhibitors for NSCLC Consumption Share by End-Users from 2016 to 2027

    • Figure Northeast China Targeted Drug BRAF Inhibitors for NSCLC Consumption Share by End-Users in 2016

    • Figure Northeast China Targeted Drug BRAF Inhibitors for NSCLC Consumption Share by End-Users in 2021

    • Figure Northeast China Targeted Drug BRAF Inhibitors for NSCLC Consumption Share by End-Users in 2027

    • Table Southwest China Targeted Drug BRAF Inhibitors for NSCLC Consumption by Types from 2016 to 2027

    • Table Southwest China Targeted Drug BRAF Inhibitors for NSCLC Consumption Share by Types from 2016 to 2027

    • Figure Southwest China Targeted Drug BRAF Inhibitors for NSCLC Consumption Share by Types in 2016

    • Figure Southwest China Targeted Drug BRAF Inhibitors for NSCLC Consumption Share by Types in 2021

    • Figure Southwest China Targeted Drug BRAF Inhibitors for NSCLC Consumption Share by Types in 2027

    • Table Southwest China Targeted Drug BRAF Inhibitors for NSCLC Consumption by End-Users from 2016 to 2027

    • Table Southwest China Targeted Drug BRAF Inhibitors for NSCLC Consumption Share by End-Users from 2016 to 2027

    • Figure Southwest China Targeted Drug BRAF Inhibitors for NSCLC Consumption Share by End-Users in 2016

    • Figure Southwest China Targeted Drug BRAF Inhibitors for NSCLC Consumption Share by End-Users in 2021

    • Figure Southwest China Targeted Drug BRAF Inhibitors for NSCLC Consumption Share by End-Users in 2027

    • Table Northwest China Targeted Drug BRAF Inhibitors for NSCLC Consumption by Types from 2016 to 2027

    • Table Northwest China Targeted Drug BRAF Inhibitors for NSCLC Consumption Share by Types from 2016 to 2027

    • Figure Northwest China Targeted Drug BRAF Inhibitors for NSCLC Consumption Share by Types in 2016

    • Figure Northwest China Targeted Drug BRAF Inhibitors for NSCLC Consumption Share by Types in 2021

    • Figure Northwest China Targeted Drug BRAF Inhibitors for NSCLC Consumption Share by Types in 2027

    • Table Northwest China Targeted Drug BRAF Inhibitors for NSCLC Consumption by End-Users from 2016 to 2027

    • Table Northwest China Targeted Drug BRAF Inhibitors for NSCLC Consumption Share by End-Users from 2016 to 2027

    • Figure Northwest China Targeted Drug BRAF Inhibitors for NSCLC Consumption Share by End-Users in 2016

    • Figure Northwest China Targeted Drug BRAF Inhibitors for NSCLC Consumption Share by End-Users in 2021

    • Figure Northwest China Targeted Drug BRAF Inhibitors for NSCLC Consumption Share by End-Users in 2027

    • Table Company Profile and Development Status of BeiGene

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of BeiGene

    • Figure Sales and Growth Rate Analysis of BeiGene

    • Figure Revenue and Market Share Analysis of BeiGene

    • Table Product and Service Introduction of BeiGene

    • Table Company Profile and Development Status of Novartis

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Novartis

    • Figure Sales and Growth Rate Analysis of Novartis

    • Figure Revenue and Market Share Analysis of Novartis

    • Table Product and Service Introduction of Novartis


Report Version Choose

Report

BUY NOW

Our Customers

Beyond grateful for the confidence and support from all partners and customers.A win-win situation is our ultimate pursuit.

Beyond Consulting, Future is Feasible

We provide more professional and intelligent market reports to complement your business decisions.

CONTACT US